- Home
- HYPR vs ACET Comparison
HYPR vs ACET Comparison
Compare HYPR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- ACET
- Stock Information
- Founded
- HYPR 2014
- ACET 1947
- Country
- HYPR United States
- ACET United States
- Employees
- HYPR N/A
- ACET N/A
- Industry
- HYPR Medical Specialities
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- ACET Health Care
- Exchange
- HYPR Nasdaq
- ACET Nasdaq
- Market Cap
- HYPR 55.9M
- ACET 49.3M
- IPO Year
- HYPR N/A
- ACET N/A
- Fundamental
- Price
- HYPR $1.39
- ACET $0.66
- Analyst Decision
- HYPR Strong Buy
- ACET Strong Buy
- Analyst Count
- HYPR 3
- ACET 7
- Target Price
- HYPR $1.28
- ACET $5.60
- AVG Volume (30 Days)
- HYPR 482.9K
- ACET 557.0K
- Earning Date
- HYPR 08-13-2025
- ACET 08-07-2025
- Dividend Yield
- HYPR N/A
- ACET N/A
- EPS Growth
- HYPR N/A
- ACET N/A
- EPS
- HYPR N/A
- ACET N/A
- Revenue
- HYPR $10,797,000.00
- ACET N/A
- Revenue This Year
- HYPR $12.31
- ACET N/A
- Revenue Next Year
- HYPR $29.29
- ACET N/A
- P/E Ratio
- HYPR N/A
- ACET N/A
- Revenue Growth
- HYPR N/A
- ACET N/A
- 52 Week Low
- HYPR $0.53
- ACET $0.45
- 52 Week High
- HYPR $1.90
- ACET $1.64
- Technical
- Relative Strength Index (RSI)
- HYPR 67.19
- ACET 45.06
- Support Level
- HYPR $1.17
- ACET $0.58
- Resistance Level
- HYPR $1.55
- ACET $0.70
- Average True Range (ATR)
- HYPR 0.12
- ACET 0.05
- MACD
- HYPR 0.02
- ACET -0.01
- Stochastic Oscillator
- HYPR 70.91
- ACET 39.23
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.